← Leaderboards
Allen C Gao
University Of California At Davis
$13,767,104
Attributed
$14,937,016
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,937,016 · 11
VA$0 · 5
By mechanism
R01$14,563,595 · 9
R21$363,421 · 1
R13$10,000 · 1
I01$0 · 4
IK6$0 · 1
Top collaborators
- Pui-Kai Li7 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Pui-Kai Li$1,169,912
- Nagalakshmi Nadiminty$524,556
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroAndrogen ReceptorResistanceCellsSignal TransductionAndrogensPlayCell GrowthMediatingMalignant Neoplasm Of ProstateLncapAndrogen AntagonistsGrowthProstate Cancer CellOverexpressionAbirateronePathway InteractionsProstate Cancer ProgressionTherapy ResistantCastration Resistant Prostate CancerTumorResistance DevelopmentKnock-Down
Grant awards (73)
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$521,811
R01 · FY2025 · CA · contact PI
Therapeutic targeting Wnt5A signaling for advanced prostate cancer$367,236
R01 · FY2025 · CA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$88,514
R01 · FY2025 · CA · contact PI
Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer$0
I01 · FY2025 · VA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$507,346
R01 · FY2024 · CA · contact PI
Therapeutic targeting Wnt5A signaling for advanced prostate cancer$356,964
R01 · FY2024 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$333,896
R01 · FY2024 · CA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$83,979
R01 · FY2024 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$74,244
R01 · FY2024 · CA · contact PI
BLR&D Research Career Scientist Award$0
IK6 · FY2024 · VA · contact PI
Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer$0
I01 · FY2024 · VA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$521,104
R01 · FY2023 · CA · contact PI
Therapeutic targeting Wnt5A signaling for advanced prostate cancer$374,008
R01 · FY2023 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$351,830
R01 · FY2023 · CA · contact PI
Targeting AR variants in advanced prostate cancer$351,775
R01 · FY2023 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$76,589
R01 · FY2023 · CA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$73,643
R01 · FY2023 · CA · contact PI
BLR&D Research Career Scientist Award$0
IK6 · FY2023 · VA · contact PI
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$543,427
R01 · FY2022 · CA · contact PI
Therapeutic targeting Wnt5A signaling for advanced prostate cancer$377,221
R01 · FY2022 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$358,910
R01 · FY2022 · CA · contact PI
Targeting AR variants in advanced prostate cancer$351,775
R01 · FY2022 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$73,348
R01 · FY2022 · CA · contact PI
BLR&D Research Career Scientist Award$0
IK6 · FY2022 · VA · contact PI
Novel mechanisms of resistance to antiandrogen therapies$0
I01 · FY2022 · VA · contact PI
Therapeutic targeting Wnt5A signaling for advanced prostate cancer$397,216
R01 · FY2021 · CA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$373,143
R01 · FY2021 · CA · contact PI
Targeting AR variants in advanced prostate cancer$358,955
R01 · FY2021 · CA · contact PI
Novel mechanisms of resistance to antiandrogen therapies$0
I01 · FY2021 · VA · contact PI
BLR&D Research Career Scientist Award$0
IK6 · FY2021 · VA · contact PI
Therapeutic targeting steroid sulfatase for advanced prostate cancer$387,245
R01 · FY2020 · CA · contact PI
Targeting AR variants in advanced prostate cancer$358,955
R01 · FY2020 · CA · contact PI
BLR&D Research Career Scientist Award$0
IK6 · FY2020 · VA · contact PI
Novel mechanisms of resistance to antiandrogen therapies$0
I01 · FY2020 · VA · contact PI
Targeting AR variants in advanced prostate cancer$373,205
R01 · FY2019 · CA · contact PI
Novel mechanisms of resistance to antiandrogen therapies$0
I01 · FY2019 · VA · contact PI
Novel mechanisms of resistance to antiandrogen therapies$0
I01 · FY2018 · VA · contact PI
Novel roles of microRNA in androgen receptor signaling$308,025
R01 · FY2017 · CA · contact PI
The role of p52 in prostate cancer$0
I01 · FY2017 · VA · contact PI
Novel roles of microRNA in androgen receptor signaling$309,073
R01 · FY2016 · CA · contact PI
The role of p52 in prostate cancer$0
I01 · FY2016 · VA · contact PI
Novel roles of microRNA in androgen receptor signaling$310,025
R01 · FY2015 · CA · contact PI
The role of p52 in prostate cancer$0
I01 · FY2015 · VA · contact PI
Novel roles of microRNA in androgen receptor signaling$310,892
R01 · FY2014 · CA · contact PI
Interleukin-6 and castration-resistant prostate cancer$295,504
R01 · FY2014 · CA · contact PI
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist$162,451
R21 · FY2014 · CA · contact PI
Omics in Urologic Research-New Frontiers Driving Precision Medicine$10,000
R13 · FY2014 · DK · contact PI
The role of p52 in prostate cancer$0
I01 · FY2014 · VA · contact PI
Novel roles of microRNA in androgen receptor signaling$311,679
R01 · FY2013 · CA · contact PI
Interleukin-6 and castration-resistant prostate cancer$286,785
R01 · FY2013 · CA · contact PI
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist$200,970
R21 · FY2013 · CA · contact PI
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer$0
I01 · FY2013 · VA · contact PI
Interleukin-6 and castration-resistant prostate cancer$305,534
R01 · FY2012 · CA · contact PI
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer$0
I01 · FY2012 · VA · contact PI
Interleukin-6 and castration-resistant prostate cancer$304,686
R01 · FY2011 · CA · contact PI
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer$0
I01 · FY2011 · VA · contact PI
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer$0
I01 · FY2011 · VA · contact PI
Interleukin-6 and castration-resistant prostate cancer$313,560
R01 · FY2010 · CA · contact PI
Selenium regulates androgen receptor signaling in prostate cancer$235,778
R01 · FY2010 · CA · contact PI
Selenium regulates androgen receptor signaling in prostate cancer$235,778
R01 · FY2009 · CA · contact PI
IL-4 and androgen receptor signaling in prostate cancer$213,141
R01 · FY2009 · CA · contact PI
Selenium regulates androgen receptor signaling in prostate cancer$235,778
R01 · FY2008 · CA · contact PI
IL-4 and androgen receptor signaling in prostate cancer$213,141
R01 · FY2008 · CA · contact PI
Selenium regulates androgen receptor signaling in prostate cancer$260,568
R01 · FY2007 · CA · contact PI
IL-4 and androgen receptor signaling in prostate cancer$222,210
R01 · FY2007 · CA · contact PI
Selenium regulates androgen receptor signaling in prostate cancer$265,186
R01 · FY2006 · CA · contact PI
IL-4 and androgen receptor signaling in prostate cancer$226,463
R01 · FY2006 · CA · contact PI
IL-4 and androgen receptor signaling in prostate cancer$229,542
R01 · FY2005 · CA
Stat3 in Androgen Receptor Signaling in Prostate Cancer$208,816
R01 · FY2005 · CA
Stat3 in Androgen Receptor Signaling in Prostate Cancer$206,395
R01 · FY2004 · CA
Stat3 in Androgen Receptor Signaling in Prostate Cancer$204,315
R01 · FY2003 · CA
Stat3 in Androgen Receptor Signaling in Prostate Cancer$200,618
R01 · FY2002 · CA
Stat3 in Androgen Receptor Signaling in Prostate Cancer$313,764
R01 · FY2001 · CA